Feature: Peering Into My Genome
By Jennifer Couzin-Frankel,
Science
| 12. 04. 2014
Rarely could I be described in a headline in The New York Times, which explains why I lingered over one earlier this fall. “Study of Jewish Women Shows Link to Cancer Without Family History,” announced the 5 September story. Uneasily, I read on: “Women of Ashkenazi Jewish descent who tested positive for cancer-causing genetic mutations during random screenings have high rates of breast and ovarian cancer even when they have no family history of the disease, researchers reported Thursday.”
Hmmm.
Science has been my professional home for the past 13 years, and in that time I’ve written extensively about genetic testing and spoken with dozens of experts at the field’s cutting edge. I’ve chronicled the scientific advances, the ethical quandaries, the lives testing saves, the angst it ignites. I had never turned the lens on my own DNA.
Abruptly, there was no escaping it. My parents are both of Ashkenazi descent. To my knowledge, no one on either side of my family has ever had breast or ovarian cancer. But suddenly I saw how a mutation in the genes...
Related Articles
By Emily Beitiks, Guest Contributor
| 05.10.2024
If you’re looking for a book where good triumphs over evil, The Occasional Human Sacrifice: Medical Experimentation and the Cost of Saying No, isn’t it. But hear me out: you were looking for the wrong book, and you will understand why if you give this a read.
Carl Elliott, Professor of Philosophy and Medical Ethics at the University of Minnesota, provides a nuanced look into the history of medical research scandals and the whistleblowers who bring these stories...
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Eric Schmidt, TIME | 04.16.2024
Imagine a world where everything from plastics to concrete is produced from biomass. Personalized cell and gene therapies prevent pandemics and treat previously incurable genetic diseases. Meat is lab-grown; enhanced nutrient grains are climate-resistant. This is what the future could...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...